AstraZeneca looks for alliance to share drug development costs, FT says

June 23, 2013

Reflecting the growing trend for drugmakers to share costs and risks of developing new drugs, AstraZeneca is considering a big strategic alliance with another pharmaceutical company to share the costs and benefits of experimental drug development, the Financial Times says.